China-based Biosion, Inc’s US partner Pyxis Oncology, Inc. (NASDAQ: PYXS) announced receiving clinical trial approval from the US FDA for its PYX-106 (BSI-060T). The anti-Siglec-15 monoclonal antibody (mAb) can now be assessed in clinics in bladder cancer, bile duct cancer, colorectal cancer, kidney cancer, and more.
Preclinical Data and Drug Potential
Preclinical data have shown that BSI-060T has higher affinity, stronger biological activity, and longer half-life compared with the standard drug, indicating that the drug holds best-in-class potential. Studies have proved that the Siglec-15 mediated tumor immunosuppression signal pathway and the PD-L1/PD-1 signal pathway do not overlap each other, suggesting a potential synergistic anti-tumor mechanism. The drug is therefore expected to be developed in combination with other therapies in future.
Licensing Deal and Future Plans
Pyxis Oncology struck a USD 232.5 million licensing deal with Biosion in March this year, taking exclusive development and commercialization rights to the drug outside of Greater China.-Fineline Info & Tech
